Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients. Materials and Methods Advanced BTC patients with a good performance status (Eastern Cooperative Oncology Group [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis. Results In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052). Conclusion Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.
Abstract
Purpose Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients. Materials and Methods Advanced BTC patients with a good performance status (Eastern Cooperative Oncology Group [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis. Results In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052). Conclusion Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.
참고문헌 (16)
- Huguier M, "Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer", Hepatogastroenterology, 48, pp.875~878 (2001)
- Mallinson CN, "Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial", Br Med J, 281, pp.1589~1591 (1980)[DOI]
- Palmer KR, "Chemotherapy prolongs survival in inoperable pancreatic carcinoma", Br J Surg, 81, pp.882~885 (1994)[DOI]
- Brieau B, "Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Enterologues Oncologues", Cancer, 121, pp.3290~3297 (2015)[DOI]
- Fornaro L, "Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data", J Exp Clin Cancer Res, 34, pp.156~ (2015)[DOI]
- Ji JH, "Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC)", Jpn J Clin Oncol, 45, pp.256~260 (2015)[DOI]
- Valle JW, "Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study: The UK ABC-01 Study", Br J Cancer, 101, pp.621~627 (2009)[DOI]
- Jongha Park, "Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study", Gut and Liver, 3(4), pp.298~305 (2009), 거트앤리버 소화기연관학회협의회
- Sharma A, "Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study", J Clin Oncol, 28, pp.4581~4586 (2010)[DOI]
- Sjolander A, "Propensity scores and M-structures", Stat Med, 28, pp.1416~1420 (2009)[DOI]
- Ahmann DL, "An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis", Am J Clin Oncol, 5, pp.355~358 (1982)[DOI]
- Yu KD, "Association between delayed initiation of adjuvant CMF or anthracyclinebased chemotherapy and survival in breast cancer: a systematic review and meta-analysis", BMC Cancer, 13, pp.240~ (2013)[DOI]
- Biagi JJ, "Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis", JAMA, 305, pp.2335~2342 (2011)[DOI]
- Des Guetz G, "Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis", Eur J Cancer, 46, pp.1049~1055 (2010)[DOI]
- Gagliato Dde M, "Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer", J Clin Oncol, 32, pp.735~744 (2014)[DOI]
- Ackland SP, "A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer", Br J Cancer, 93, pp.1236~1243 (2005)[DOI]